Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec 16;12(12):2074.
doi: 10.3390/jpm12122074.

Outcomes after Transcatheter Mitral Valve Implantation: A Literature Review

George Samanidis  1 , Meletios Kanakis  2 , Konstantinos Perreas  1
Affiliations
Review

Outcomes after Transcatheter Mitral Valve Implantation: A Literature Review

George Samanidis et al. J Pers Med. .

Abstract

Mitral valve disease is the most common heart valve disease worldwide. Surgical mitral valve replacement or repair has been an established therapy in patients with severe mitral valve disease for many years. On the other hand, many patients with advanced mitral valve disease and severe comorbidities are treated conservatively and are excluded from the surgical procedure. Furthermore, in patients with severe comorbidities, transcatheter mitral valve repair by edge-to-edge technique with MitraClip or transcatheter mitral valve repair with a non-absorbable ring have been added as therapeutic options over the last few years. Alternative procedures for the treatment of patients with advanced prosthetic or native mitral valve diseases include transcatheter access for replacement or implantation of a new prosthetic valve in the diseased mitral valve. Promising results were published about short-term outcomes of patients who underwent the transcatheter mitral valve replacement. The current view and results of the transcatheter mitral valve implantation in patients with advanced native or prosthetic mitral valve disease are briefly discussed.

Keywords: implantation; mitral valve; replacement; transcatheter.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Writing Committee Members. Otto C.M., Nishimura R.A., Bonow R.O., Carabello B.A., Erwin J.P., 3rd, Gentile F., Jneid H., Krieger E.V., Mack M., et al. 2020 ACC/AHA Guideline for the Management of Patients with Valvular Heart Diseass: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 2021;77:e25–e197. doi: 10.1016/j.jacc.2020.11.018. - DOI - PubMed
    1. Beyersdorf F., Vahanian A., Milojevic M., Praz F., Baldus S., Bauersachs J., Capodanno D., Conradi L., De Bonis M., De Paulis R., et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur. J. Cardio-Thoracic Surg. 2021;60:727–800. doi: 10.1093/ejcts/ezab389. - DOI - PubMed
    1. Izumi C., Eishi K., Ashihara K., Arita T., Otsuji Y., Kunihara T., Komiya T., Shibata T., Seo Y., Daimon M., et al. JCS/JSCS/JATS/JSVS 2020 Guidelines on the Management of Valvular Heart Disease. Circ. J. 2020;84:2037–2119. doi: 10.1253/circj.CJ-20-0135. - DOI - PubMed
    1. Godino C., Scotti A., Taramasso M., Adamo M., Russo M., Chiarito M., Melillo F., Beneduce A., Pivato C.A., Arrigoni L., et al. Two-year cardiac mortality after MitraClip treatment of functional mitral regurgitation in ischemic and non-ischemic dilated cardiomyopathy. Int. J. Cardiol. 2018;269:33–39. doi: 10.1016/j.ijcard.2018.06.041. - DOI - PubMed
    1. Messika-Zeitoun D., Nickenig G., Latib A., Kuck K.-H., Baldus S., Schueler R., La Canna G., Agricola E., Kreidel F., Huntgeburth M., et al. Transcatheter mitral valve repair for functional mitral regurgitation using the Cardioband system: 1 year outcomes. Eur. Heart J. 2018;40:466–472. doi: 10.1093/eurheartj/ehy424. - DOI - PubMed

LinkOut - more resources